Imagine Pharma
Biotechnology company developing a proprietary peptide (IMG-1) across three platforms — oral biologics delivery, therapeutics, and regenerative medicine — with active programs in oral peptide delivery, wound therapeutics, and islet cell regeneration/isolation. Provides research and clinical islet isolation services, cell propagation methods for progenitor cells, and commercial/licensing activity for a peptide-based functional ingredient and dietary supplements.
Industries
Nr. of Employees
small (1-50)
Imagine Pharma
Patents
Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US-11612637-B2
View DetailsCompositions and methods for treating diabetes, hypertension and hypercholesterolemia
US-10751384-B2
View DetailsCompositions and methods for treating diabetes, hypertension and hypercholesterolemia
US-10548941-B2
View Details
Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US-11612637-B2
View DetailsCompositions and methods for treating diabetes, hypertension and hypercholesterolemia
US-10751384-B2
View DetailsCompositions and methods for treating diabetes, hypertension and hypercholesterolemia
US-10548941-B2
View DetailsProducts
Oral erythropoietin program (PT-1)
Oral formulation program aiming to deliver erythropoietin orally using a peptide-mediated transport system to treat anemia indications traditionally requiring injectable erythropoietin.
Oral GLP-1 agonist program (PT-3)
Program to develop an oral GLP-1 receptor agonist using an oral peptide transporter to address type 2 diabetes therapy via oral dosing.
Topical skin graft and wound healing therapeutics (Top-1, Top-2)
Therapeutic programs focused on accelerating re-epithelialization and healing in donor skin graft sites and diabetic wounds, supported by preclinical efficacy studies.
Activated insulin-producing cell (AIPC) programs
Generation and propagation of insulin-producing islet cell populations from human pancreatic tissue, intended for research, clinical autologous transplant, and cell-therapy collaborations.
Peptide-based functional ingredient and dietary supplements (Progenalen)
Peptide-based functional ingredient offered as raw material and finished supplements for professional and consumer channels; available in liquid drops and capsules for wellness and healthy aging support.
Pancreatic Tissue
Establishment of protocols for the fixation and preservation of pancreatic tissue from human organ donors to serve scientific research needs.
Oral erythropoietin program (PT-1)
Oral formulation program aiming to deliver erythropoietin orally using a peptide-mediated transport system to treat anemia indications traditionally requiring injectable erythropoietin.
Oral GLP-1 agonist program (PT-3)
Program to develop an oral GLP-1 receptor agonist using an oral peptide transporter to address type 2 diabetes therapy via oral dosing.
Topical skin graft and wound healing therapeutics (Top-1, Top-2)
Therapeutic programs focused on accelerating re-epithelialization and healing in donor skin graft sites and diabetic wounds, supported by preclinical efficacy studies.
Activated insulin-producing cell (AIPC) programs
Generation and propagation of insulin-producing islet cell populations from human pancreatic tissue, intended for research, clinical autologous transplant, and cell-therapy collaborations.
Peptide-based functional ingredient and dietary supplements (Progenalen)
Peptide-based functional ingredient offered as raw material and finished supplements for professional and consumer channels; available in liquid drops and capsules for wellness and healthy aging support.
Pancreatic Tissue
Establishment of protocols for the fixation and preservation of pancreatic tissue from human organ donors to serve scientific research needs.
Services
Clinical-grade human islet isolation and preparation for total pancreatectomy and autologous islet transplantation performed for hospital systems; also performed at partner contract facilities.
On-demand research-grade islet isolations, pancreatic tissue processing, living pancreatic slices, and tissue/cell banking for the diabetes research community.
Establishment of research islet labs, hands-on or group training in islet isolation and culture, and protocol optimization and troubleshooting.
Preclinical efficacy testing using rodent models for wound healing and metabolic endpoints to support therapeutic program progression.
Licensing and exclusive distribution arrangements for a peptide-based functional ingredient and professional-grade dietary supplement products; white-label and raw-material offerings for partners.
Clinical-grade human islet isolation and preparation for total pancreatectomy and autologous islet transplantation performed for hospital systems; also performed at partner contract facilities.
On-demand research-grade islet isolations, pancreatic tissue processing, living pancreatic slices, and tissue/cell banking for the diabetes research community.
Establishment of research islet labs, hands-on or group training in islet isolation and culture, and protocol optimization and troubleshooting.
Preclinical efficacy testing using rodent models for wound healing and metabolic endpoints to support therapeutic program progression.
Licensing and exclusive distribution arrangements for a peptide-based functional ingredient and professional-grade dietary supplement products; white-label and raw-material offerings for partners.
Expertise Areas
- Oral biologics delivery
- Islet isolation and transplantation services
- Regenerative medicine and progenitor cell expansion
- Preclinical development and animal models
Key Technologies
- Peptide-mediated endocytosis for oral biologic transport
- Activated islet progenitor cell generation and expansion
- Clinical human islet isolation techniques
- Pancreatic tissue slicing and living pancreatic slices
News & Updates
Research collaboration to combine propagated insulin-producing cells with an ectopic organ growth platform to advance preclinical proof-of-concept for type 1 diabetes therapies.
Creation of a nonprofit to advance metabolic research and increase access to treatments, with a focus on veterans.
Announcement of $32.5M Series A financing to support preclinical and commercialization initiatives across platforms.
Selected as an approved Islet Isolation Center under the NIDDK Integrated Islet Distribution Program to supply high-quality islets to the research community.
Reported completion of dozens of clinical human islet isolation procedures for leading hospitals (multiple press releases cite 32+ in 2023 and 31 clinical TPAITs in 2024 with additional procedures in 2025).
Signed an exclusive distribution and licensing agreement for professional-channel distribution of a peptide-based dietary supplement.
Research collaboration to combine propagated insulin-producing cells with an ectopic organ growth platform to advance preclinical proof-of-concept for type 1 diabetes therapies.
Creation of a nonprofit to advance metabolic research and increase access to treatments, with a focus on veterans.
Announcement of $32.5M Series A financing to support preclinical and commercialization initiatives across platforms.
Selected as an approved Islet Isolation Center under the NIDDK Integrated Islet Distribution Program to supply high-quality islets to the research community.
Reported completion of dozens of clinical human islet isolation procedures for leading hospitals (multiple press releases cite 32+ in 2023 and 31 clinical TPAITs in 2024 with additional procedures in 2025).
Signed an exclusive distribution and licensing agreement for professional-channel distribution of a peptide-based dietary supplement.